… natural history of premanifest HD progression in … clinical markers of premanifest disease
progression. Findings are interpreted in terms of their utilitarian value for preventive clinical trials…

… and clinical markers of premanifest disease progression. Findings are interpreted in terms of
their utilitarian value for preventive clinical trials. … sizes for randomized clinical trials (RCTs). …

… is the identification of state biomarkers that can be used in pre-manifest HD gene carriers to
… 5], suggesting sample sizes that are feasible for use in clinical trials. The robustness of these …

… trial in premanifest and prodromal individuals with the gene expansion for Huntington disease
is highly feasible … Although searches for new biomarkers and refined clinical markers are …

… feasibility of preventive clinical trials in prodromal Huntington … group, a gap may exist between
the TRACK-HD premanifest … The TRACK-HD premanifest group may be comparable to the …

… We show longitudinal change over 12 months in generalised and regional brain volume, …
disease onset and show the feasibility of obtaining quantifiable endpoints for future trials. …

… Our results demonstrate the feasibility of prevention trials for HD and the safety of high-…
premanifest Huntington disease (PHD) subjects randomized to creatine were similar to changes …

… The single exception was a safety and feasibility trial conducted in premanifest HD. … Using
disease-progression biomarkers in the trial design as possible outcomes—namely, structural …

… clinical trials by reducing the duration and numbers required for such studies. This is especially
true in younger premanifest … strengths and have a feasible acquisition time - particularly …

… be utilized in premanifest cohorts in clinical trials to reduce … biomarkers is reliable, and that
this type of study is feasible in … thereby reducing the burden of clinical trials , with the goal of …